Actively Recruiting

Age: 18Years +
All Genders
ID06343051

Ultrasound Hemodynamic Assessment in Newly Diagnosed Fetal Growth Restriction: A Pilot Study

Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-02-10

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of an ultrasound measurement system called USCOM for patients with newly diagnosed fetal growth restriction (FGR). This observational study aims to understand how well the heart pumps blood during pregnancy when FGR is diagnosed after 27 weeks and 6 days of gestation. The study is sponsored by the Icahn School of Medicine at Mount Sinai and focuses on heart function in relation to pregnancy complications. Participants with a new diagnosis of fetal growth restriction will be monitored using the USCOM device, which measures the amount of blood pumped in and out of the heart. This measurement will be taken every 2 to 4 weeks during routine prenatal ultrasounds until the pregnancy ends. The study observes changes in systemic vascular resistance as the main outcome. Throughout the study, participants will undergo regular prenatal ultrasounds with USCOM assessments to track heart function and blood flow. Researchers will collect data on systemic vascular resistance at these intervals. The study continues until delivery, with no additional treatment given, focusing on observation and monitoring. Total participation time varies depending on when the diagnosis occurs during pregnancy.

CONDITIONS

Brief Title

USCOM in Newly Diagnosed FGR Cases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pregnant patients with a new diagnosis of fetal growth restriction (estimated fetal weight <10th percentile or abdominal circumference <10th percentile) in the third trimester (gestational age >27w6d)
Not Eligible

You will not qualify if you...

  • Multiple gestation
  • Fetal anomalies
  • Gestational diabetes or pregestational diabetes

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Implementation

Duration - From diagnosis until the end of pregnancy

Participants undergo ultrasound hemodynamic assessments using the USCOM device to measure blood flow in the heart.

Visits every 2 to 4 weeks at the time of prenatal ultrasound

Trial Site Locations

Total: 1 location

1

Mount Sinai Hospital

New York, New York, United States, 10029

Actively Recruiting

Loading map...

Research Team

N

Nicola F Tavella, MPH

A

Allison Perelman, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Impact of Maternal Left-Lateral Recumbent Positioning in Pre...

Fetal Growth Restriction

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here